InhaleRx Completes Tranche 1 of Capital Raising With $600,000 Secured

InhaleRx Limited ( (AU:IRX) ) has issued an update.

InhaleRx Limited has completed the first tranche of its equity placement, receiving a final $172,500 and issuing 6.9 million ordinary shares at $0.025 each, bringing total funds raised under Tranche 1 to $600,000 before costs as part of a broader $750,000 placement managed by Peak Asset Management and placed with professional and sophisticated investors. Investors in the placement are entitled to one free attaching option for every two shares, exercisable at $0.042 for two years, while additional options to Peak and a $35,000 participation by director Ron Wise remain subject to shareholder approval at a general meeting on 29 January 2026, underscoring ongoing capital-raising efforts to support the company’s clinical development programs and strengthen its position in the specialised inhaled-therapies market.

The most recent analyst rating on (AU:IRX) stock is a Hold with a A$0.02 price target. To see the full list of analyst forecasts on InhaleRx Limited stock, see the AU:IRX Stock Forecast page.

More about InhaleRx Limited

InhaleRx Limited (ASX: IRX) is an Australian clinical-stage drug development company specialising in rapid-onset inhaled therapies targeting unmet medical needs in pain management and mental health. Its pipeline includes IRX-211 for breakthrough cancer pain, IRX-616a for panic disorder and SRX-25 for treatment-resistant depression, with a strategic focus on pursuing U.S. FDA approval via expedited regulatory pathways and addressing gaps in current treatments that raise dependency concerns.

Average Trading Volume: 288,920

Technical Sentiment Signal: Strong Sell

Current Market Cap: A$5.51M

See more data about IRX stock on TipRanks’ Stock Analysis page.